PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10453401

BMIPP in angina pectoris.

S Nishimura·Y Ohta
View original source ↗Export metadata ↓

Abstract

Radionuclide imaging with BMIPP for assessment of myocardial metabolism can assist in clinical decision making in certain subsets of patients with coronary artery disease. In stable angina, abnormal BMIPP imaging and less BMIPP uptake than Tl-201 are more likely to be seen in the distribution of vessels with severe stenoses and related to regional wall abnormalities. BMIPP SPECT imaging is a promising approach in the evaluation of patients with suspected unstable angina during the pain-free period even after stabilization. Fatty acid metabolism is easily suppressed due to the abrupt onset of ischaemia. In addition, combined imaging with BMIPP and Tl-201 can provide insights into the understanding of abnormal metabolism in myocardium in stable and unstable angina. This review addressed the clinical applications of BMIPP imaging for evaluation of stable and unstable angina.

Explore related subjects

Angina PectorisAngina, UnstableFatty AcidsHeartHumansIodine RadioisotopesIodobenzenesTomography, Emission-Computed, Single-PhotonJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Nishimura, Y Ohta. 1999. BMIPP in angina pectoris.. https://doi.org/10.1023/a%3A1006136300127

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris.

OBJECTIVE: Ischemic preconditioning is an increased tolerance to myocardial ischemia during the second of two consecutive exercise tests. ATP-sensitive K(+) channel blockers, such as glinides and sulfonylurea drugs, can induce loss of ischemic preconditioning. This study aimed to investigate the effects of repaglinide, a hypoglycemic agent with an affinity for myocardial ATP-sensitive K (+)channels, on the results of consecutive exercise tests in patients with diabetes and multivessel coronary artery disease. METHODS: Forty-two patients with type 2 diabetes and chronic stable angina pectoris, and two-vessel or three-vessel disease participated in this study. The patients underwent two consecutive treadmill exercise tests (phase 1). On the day after these exercise tests, 2 mg of oral repaglinide was given to the patients. One week later, two exercise tests were repeated consecutively (phase 2). RESULTS: All patients achieved 1.0-mm ST-segment depression during the four exercise tests (T1, T2, T3, and T4). In phase 2, seven patients improved in time to onset of 1.0-mm ST-segment depression. The worsening of the time to onset of 1.0-mm ST-segment depression in phase 2 demonstrated ischemic preconditioning block in 83.3% of patients (P=0.0001). Even the postexercise electrocardiographic parameters (ST-segment depression morphology and magnitude and arrhythmias) were significantly different between the groups with and without pharmacologic ischemic preconditioning block (P=0.031). CONCLUSIONS: Repaglinide, an oral hypoglycemic agent with ATP-sensitive K(+) channel-blocker activity, eliminated the myocardial ischemic preconditioning in patients with coronary disease and diabetes.

Angina Pectoris↗